Search - tctmd.com

Displaying 101 - 120 of 254

Sort: Relevancy | Date

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

News Daily News

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

June 25, 2018

NAVIGATE ESUS: Rivaroxaban Fails to Prevent More Recurrent Cryptogenic Strokes Than Aspirin

News Daily News

NAVIGATE ESUS: Rivaroxaban Fails to Prevent More Recurrent Cryptogenic Strokes Than Aspirin

May 16, 2018

Spin to Win: Results From Late Breaking Meeting Trials Often Overstated

News Daily News

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

May 15, 2018

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

May 04, 2018

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

‘Practical Guide’ for NOACs Gets an Update

News Daily News

‘Practical Guide’ for NOACs Gets an Update

March 20, 2018

Aspirin Switch for VTE Prevention After Hip/Knee Arthroplasty: Safe, Effective, and Cost-Saving in EPCAT II

News Daily News

Aspirin Switch for VTE Prevention After Hip/Knee Arthroplasty: Safe, Effective, and Cost-Saving in EPCAT II

Michael O'Riordan

February 21, 2018

Tool Predicts Stroke Risk in Patients With Systolic Dysfunction After MI

News Daily News

Tool Predicts Stroke Risk in Patients With Systolic Dysfunction After MI

February 12, 2018

Could NOACs Have a Role for Secondary Prevention After STEMI?

News Daily News

Could NOACs Have a Role for Secondary Prevention After STEMI?

February 08, 2018

TCTMD’s Top 10 Most Popular Stories for January 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for January 2018

January 31, 2018

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

News Daily News

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

January 02, 2018

The Biggest News of 2017: TCTMD’s Top 10

News Daily News

The Biggest News of 2017: TCTMD’s Top 10

January 01, 2018

Nephroprotective NOACs? Renal Dysfunction Not Infrequent Among A-fib Patients, but Some Agents Reduce Risk

News Daily News

Nephroprotective NOACs? Renal Dysfunction Not Infrequent Among A-fib Patients, but Some Agents Reduce Risk

Yael L. Maxwell

November 28, 2017

DOACs Not Associated With Major Bleeding, Mortality: Observational Analysis

News Daily News

DOACs Not Associated With Major Bleeding, Mortality: Observational Analysis

Michael O'Riordan

October 19, 2017

Blood in Urine Carries Consequences for Patients on Antithrombotics

News Daily News

Blood in Urine Carries Consequences for Patients on Antithrombotics

Yael L. Maxwell

October 09, 2017

Rivaroxaban Trial in Patients With Embolic Stroke of Undetermined Source Stopped Early

News Daily News

Rivaroxaban Trial in Patients With Embolic Stroke of Undetermined Source Stopped Early

October 09, 2017

NOAC Bleeding Risk Rises With Several Drug Combinations

News Daily News

NOAC Bleeding Risk Rises With Several Drug Combinations

Michael O'Riordan

October 06, 2017

Rivaroxaban, Warfarin Provide Similar Results Early After Mild Strokes Related to A-fib

News Daily News

Rivaroxaban, Warfarin Provide Similar Results Early After Mild Strokes Related to A-fib

September 14, 2017

Extended Low-Dose Ticagrelor May Prevent Adverse Events Post-MI, Study Finds

News Daily News

Extended Low-Dose Ticagrelor May Prevent Adverse Events Post-MI, Study Finds

Yael L. Maxwell

September 12, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.